文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

限制性液体治疗与开放性液体治疗在大型腹部手术中的比较

Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery.
PubMed 文献 · N Engl J Med · 2018-05-09
一句话结论在并发症风险增高的大型腹部手术患者中,限制性液体治疗较开放性液体治疗未提高1年无残疾生存率,且急性肾损伤发生率更高。

该国际实用型随机对照试验纳入3000例并发症风险增高的大型腹部手术患者,随机接受限制性或开放性静脉液体治疗至术后24小时。限制性组术中至术后24小时中位静脉液体入量为3.7升,开放性组为6.1升。1年无残疾生存率限制性组为81.9%,开放性组为82.3%(死亡或残疾的风险比1.05,95%CI 0.88-1.24,P=0.61)。急性肾损伤发生率限制性组为8.6%,开放性组为5.0%(P<0.001)。结论提示限制性液体方案未带来无残疾生存获益,且与急性肾损伤发生率升高相关。

要点

  • 并发症风险增高的大型腹部手术患者中,限制性液体治疗组1年无残疾生存率为81.9%,开放性液体治疗组为82.3%,两组无显著差异(HR 1.05,95%CI 0.88-1.24,P=0.61)。
  • 限制性液体组急性肾损伤发生率为8.6%,开放性液体组为5.0%,限制性组更高(P<0.001)。
  • 限制性液体组手术部位感染率为16.5%,开放性液体组为13.6%(P=0.02);肾脏替代治疗率限制性组为0.9%,开放性组为0.3%(P=0.048),但多重检验校正后组间差异不显著。
  • 限制性液体组术中至术后24小时中位静脉液体入量为3.7升(四分位距2.9-4.9),开放性液体组为6.1升(四分位距5.0-7.4)(P<0.001)。
  • 脓毒症并发症或死亡发生率限制性组为21.8%,开放性组为19.8%(P=0.19),两组无显著差异。

适用人群与场景

  • 并发症风险增高并接受大型腹部手术的患者,随机分组在术中及术后24小时内接受限制性或开放性静脉液体治疗。

处置流程与药物剂量

  • 限制性静脉液体方案:术中至术后24小时内中位静脉液体入量为3.7升(四分位距2.9-4.9)。
  • 开放性静脉液体方案:术中至术后24小时内中位静脉液体入量为6.1升(四分位距5.0-7.4)。

研究设计与关键结果

  • 研究类型为国际实用型随机对照试验,纳入3000例并发症风险增高的大型腹部手术患者,随机接受限制性或开放性静脉液体治疗。
  • 主要终点1年无残疾生存率:限制性液体组81.9% vs 开放性液体组82.3%,死亡或残疾的风险比1.05(95%CI 0.88-1.24,P=0.61)。
  • 关键次要终点急性肾损伤(30天):限制性液体组8.6% vs 开放性液体组5.0%(P<0.001)。
  • 关键次要终点肾脏替代治疗(90天):限制性液体组0.9% vs 开放性液体组0.3%(P=0.048),多重检验校正后组间差异不显著。
  • 关键次要终点脓毒症并发症、手术部位感染或死亡的复合终点:限制性液体组21.8% vs 开放性液体组19.8%(P=0.19)。
  • 手术部位感染率:限制性液体组16.5% vs 开放性液体组13.6%(P=0.02),多重检验校正后组间差异不显著。

证据类型、等级与局限

  • 证据类型:国际实用型随机对照试验(RELIEF,ClinicalTrials.gov注册号NCT01424150)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在并发症风险增高的大型腹部手术患者中,限制性静脉液体治疗较开放性液体治疗未提高1年无残疾生存率,且急性肾损伤发生率更高。
  • 限制性液体组手术部位感染率和肾脏替代治疗率数值上高于开放性液体组,但多重检验校正后组间差异不显著。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Guidelines to promote the early recovery of patients undergoing major surgery recommend a restrictive intravenous-fluid strategy for abdominal surgery. However, the supporting evidence is limited, and there is concern about impaired organ perfusion.

METHODS: In a pragmatic, international trial, we randomly assigned 3000 patients who had an increased risk of complications while undergoing major abdominal surgery to receive a restrictive or liberal intravenous-fluid regimen during and up to 24 hours after surgery. The primary outcome was disability-free survival at 1 year. Key secondary outcomes were acute kidney injury at 30 days, renal-replacement therapy at 90 days, and a composite of septic complications, surgical-site infection, or death.

RESULTS: During and up to 24 hours after surgery, 1490 patients in the restrictive fluid group had a median intravenous-fluid intake of 3.7 liters (interquartile range, 2.9 to 4.9), as compared with 6.1 liters (interquartile range, 5.0 to 7.4) in 1493 patients in the liberal fluid group (P<0.001). The rate of disability-free survival at 1 year was 81.9% in the restrictive fluid group and 82.3% in the liberal fluid group (hazard ratio for death or disability, 1.05; 95% confidence interval, 0.88 to 1.24; P=0.61). The rate of acute kidney injury was 8.6% in the restrictive fluid group and 5.0% in the liberal fluid group (P<0.001). The rate of septic complications or death was 21.8% in the restrictive fluid group and 19.8% in the liberal fluid group (P=0.19); rates of surgical-site infection (16.5% vs. 13.6%, P=0.02) and renal-replacement therapy (0.9% vs. 0.3%, P=0.048) were higher in the restrictive fluid group, but the between-group difference was not significant after adjustment for multiple testing.

CONCLUSIONS: Among patients at increased risk for complications during major abdominal surgery, a restrictive fluid regimen was not associated with a higher rate of disability-free survival than a liberal fluid regimen and was associated with a higher rate of acute kidney injury. (Funded by the Australian National Health and Medical Research Council and others; RELIEF ClinicalTrials.gov number, NCT01424150 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Myles PS, Bellomo R, Corcoran T, et al. Restrictive versus Liberal Fluid Therapy for Major Abdominal Surgery. N Engl J Med. 2018. PMID: 29742967. doi:10.1056/NEJMoa1801601

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。